Two people can be handed prescriptions for type 2 diabetes on the same afternoon, follow them exactly, and find that one has quietly lost four kilograms by the next review while the other has gained three. Neither did anything wrong. The medicines simply pull in different directions, and weight is one of the clearest places where that shows. It matters more than it sounds: weight affects blood pressure, cholesterol, joints, sleep and how well the diabetes itself responds, so a medicine’s effect on the scales is a real part of the decision rather than a footnote. This guide sets out which classes tend to reduce weight, which tend to add it, which sit roughly neutral, and why the same medicine behaves differently in different people. It is background for a better conversation with your doctor, not a reason to change anything on your own.

Key facts

  • The class matters more than the brand. Weight effects follow the mechanism, so knowing the active ingredient tells you more than the name on the box.
  • GLP-1 medicines produce the most consistent weight loss, followed by SGLT2 inhibitors, with metformin usually neutral to slightly down.
  • Insulin, sulfonylureas, pioglitazone and repaglinide tend to add weight, for reasons that differ by class.
  • DPP-4 inhibitors are broadly weight-neutral, which is sometimes exactly why they are chosen.
  • Some gain is recovered weight, not new fat. Very high blood sugar spills calories into the urine; controlling it stops that loss, and the scales can rise even when things are going right.
  • Weight is one factor among many. Kidney function, heart disease, hypoglycaemia risk, cost and supply all sit alongside it, which is why the same numbers lead to different prescriptions.
  • Never stop or swap a diabetes medicine because of weight without review. Blood sugar can move quickly, and the risk of doing this alone outweighs the benefit.

Which diabetes medicines affect weight, and how much?

Here is the shape of it in one view. The figures are typical ranges reported across trial and clinical data, not promises, and individual results sit either side of them.

ClassExamplesUsual weight effectWhy
GLP-1 receptor agonistssemaglutide, liraglutide, dulaglutideLoss, often several kg and sometimes much moreReduced appetite, earlier fullness, slower stomach emptying
Dual GIP/GLP-1 agoniststirzepatideLoss, typically the largest of any classTwo gut-hormone pathways rather than one
SGLT2 inhibitorsempagliflozin, dapagliflozin, canagliflozinModest loss, roughly 2 kg to 3 kgGlucose, and the calories with it, leaves in the urine
BiguanidesmetforminNeutral to modest lossLess glucose made by the liver, better insulin sensitivity, mild appetite effect
Amylin analoguespramlintideModest lossSlows stomach emptying and dampens appetite
DPP-4 inhibitorssitagliptin, vildagliptin, linagliptinBroadly neutralBoosts your own gut hormones, but far more gently
MeglitinidesrepaglinideModest gainPrompts insulin release around meals
Sulfonylureasglipizide, glimepiride, gliclazideGain, often around 2 kgSustained insulin release, plus eating to manage lows
ThiazolidinedionespioglitazoneGain, sometimes several kgFat storage shifts, and the body holds fluid
Insulinall typesGain, varies widely with doseInsulin is a storage signal, and calories stop leaving in the urine

Not every medicine above is stocked everywhere in the region, and a few are rarely used outside specialist care. You can see what we list under diabetes management and weight management.

The medicines that tend to reduce weight

Weight loss with these medicines is a real effect of how they work, not a bonus side effect, which is why some of them are also licensed for weight management in their own right.

GLP-1 receptor agonists are the group that changed the conversation. They imitate a gut hormone that signals fullness and slows how quickly the stomach empties, so people eat less without fighting themselves at every meal. StatPearls describes the class acting on both glucose control and appetite regulation. Singapore’s National University Health System puts the class plainly: it increases insulin secretion, reduces appetite, slows digestion and causes weight loss. That last part is an effect of the medicine, not a promise to you, and it works alongside changes to diet and activity rather than instead of them. We cover the oral form in more detail in semaglutide tablets in Asia.

Tirzepatide works on two gut-hormone pathways rather than one and generally produces the largest reductions of any class. It is worth knowing the name, because it comes up constantly in weight conversations, though availability across Asia is patchy and it is not something we list.

SGLT2 inhibitors take a different route entirely. Rather than touching appetite, they make the kidneys pass glucose into the urine, so a few hundred calories a day leave the body. The result is a modest, steady loss of roughly 2 kg to 3 kg for most people, some of it fluid in the first weeks. NUHS describes the mechanism in four words: increases glucose excretion in urine. This class carries its own safety points, including a risk of genital and urinary infections and a rare but serious form of ketoacidosis, and the FDA maintains postmarket safety information for prescribers and patients.

Metformin sits at the boundary. It is usually the first medicine offered, and it is generally described as weight-neutral to mildly weight-reducing. StatPearls calls it weight-neutral with the potential for modest weight loss, which in this company is its own kind of advantage.

The medicines that tend to add weight

Gain in this group is not a sign the medicine is failing. In several cases it is the visible side of the medicine doing precisely what it was prescribed to do.

Insulin is the clearest example. Insulin is the body’s storage signal, so more of it available means more glucose moved into cells rather than left circulating. There is a second, less obvious reason: when blood sugar runs very high, the body dumps glucose and its calories into the urine, which is why Hong Kong’s Centre for Health Protection lists weight loss among the symptoms of diabetes itself, alongside thirst and excessive urination. Restoring control closes that leak. Some of the weight that appears afterwards is weight the body should have been keeping all along. Dose matters a great deal here, and so does how often lows are happening.

Sulfonylureas such as glipizide, glimepiride and gliclazide push the pancreas to release more insulin steadily through the day, with a typical gain of around 2 kg. They also carry a genuine risk of hypoglycaemia, and the eating needed to correct or pre-empt a low adds its own calories. NUHS names weight gain and hypoglycaemia as the side effects to weigh when choosing between the oral options, and lists gliclazide, glipizide and glimepiride among them.

Thiazolidinediones, of which pioglitazone is the one still in regular use, work by making tissues more sensitive to insulin. StatPearls covers the class in detail. Two things drive the weight change: fat is stored differently, and the body holds on to fluid. That fluid matters clinically as well as cosmetically, which is why this medicine is used cautiously in people with heart failure. The fluid part is common rather than rare: StatPearls reports dose-related fluid retention in up to 20% of people taking this class, and notes the risk is higher for anyone already swollen or also using insulin.

Meglitinides such as repaglinide act on the same insulin-release mechanism as sulfonylureas but faster and for a shorter time, taken around meals. The weight effect is usually smaller for the same reason.

The medicines that mostly leave weight alone

DPP-4 inhibitors are the quiet option, and being weight-neutral is often the point of choosing them. Sitagliptin, vildagliptin and linagliptin work on the same gut-hormone system as GLP-1 medicines, but indirectly: they stop your own hormones being broken down so quickly. The effect on appetite is far gentler, so weight generally holds steady. All three are listed together as the DPP-4 option in NUHS’s rundown of type 2 medicines, which is also a reminder of how they appear locally: Januvia, Galvus and Trajenta on Singapore shelves. For someone whose weight is already where they want it, and whose main need is better numbers without hypoglycaemia, that neutrality is a feature.

Why the same medicine does different things to different people

Ranges exist because weight is not set by the prescription alone. A handful of factors explain most of the spread.

Where you started matters. People carrying more weight at the outset tend to lose more on the medicines that reduce it, and gain effects tend to be larger at higher insulin doses.

How well controlled your diabetes was before matters just as much, and this is the part most often misread. If sugar was running very high, calories were leaving in your urine. Any treatment that fixes that will show up on the scales, and reading it as the medicine “making you fat” gets the situation backwards.

Hypoglycaemia changes eating. On the classes that can cause lows, treating and anticipating them adds food to the day that has nothing to do with hunger. Fewer lows often means less of this.

Fluid is not fat. With pioglitazone in particular, and in the first weeks of an SGLT2 inhibitor in the other direction, some of the movement is water. It arrives faster than fat ever does, which is a useful clue.

Everything else is still running. Diet, activity, sleep, stress, and other medicines that carry their own weight effects, including some antidepressants and steroids, all sit in the same picture. HealthHub’s healthy eating and physical activity guidance from Singapore’s Ministry of Health remains the foundation under any prescription, and the World Health Organization treats obesity as a chronic condition managed over years rather than a short project.

What this means if you live in or move around Asia

The pharmacology is the same everywhere. What changes across the region is the brand on the box, what is stocked, and how easily you can keep taking the same thing.

Brand names shift between markets while the molecule stays put. The same metformin or empagliflozin can appear under names you have never seen, which is why we group everything by active ingredient: it is the one label that travels. If you are moving between countries, matching the ingredient and strength rather than the brand is what keeps a regimen intact.

Continuity is worth planning for. A medicine that suits you is only useful if you can still get it in three months, and a gap can undo months of steady numbers. Our country guides cover the practicalities, including Singapore, Thailand and Malaysia, and diabetes in Singapore goes further into managing type 2 in one market.

Take the counterfeit risk seriously, especially with GLP-1 medicines. Demand for weight loss has produced a large trade in fake pens and tablets, where the dose or even the substance is wrong. Singapore’s Health Sciences Authority has warned repeatedly about buying health products from unverified online sellers. Use a registered pharmacy and check the pack.

Above all, do not treat a weight effect as a reason to stop. A medicine that is holding your blood sugar steady is doing the job it was given. If the weight direction is wrong for you, that is a case for a review, where the options include a different class, a dose change, or adding something that pulls the other way.

What to ask at your next appointment

Bringing specifics turns a vague worry into a decision that can actually be made.

  • Which of my medicines is most likely to be moving my weight, and in which direction?
  • Is what I am seeing likely to be fat, fluid, or weight I lost while my sugar was high?
  • If weight is a priority for me, is there a class that would suit my kidneys, heart and hypoglycaemia risk as well as this one does?
  • Would a dose change achieve the same control with less effect on my weight?
  • What would you want me to report between now and the next review?

Common questions

Will metformin make me lose weight? Usually not much on its own. It is best thought of as weight-neutral with a mild downward tendency, which is different from a weight-loss medicine.

My weight went up when my blood sugar finally came under control. Is the medicine wrong? Not necessarily, and this is common. High sugar was carrying calories out in your urine, and stopping that changes the balance. It is worth raising, but it is not automatically a sign of a bad fit.

Can I take a GLP-1 medicine just for weight loss? Some are licensed for weight management, but for people who meet specific clinical criteria, after an assessment, with monitoring, and alongside diet and activity. That assessment is the part that keeps it safe.

Is weight gain from a diabetes medicine reversible? Often, at least in part, whether through a dose change, a different class, or the diet and activity work that runs underneath all of this. It is a question for your prescriber rather than something to solve by stopping.

The bottom line

Weight effects split along mechanism. GLP-1 medicines and, to a lesser degree, SGLT2 inhibitors tend to reduce weight; insulin, sulfonylureas, pioglitazone and repaglinide tend to add it; metformin and the DPP-4 inhibitors sit near neutral. Knowing which class you are on explains most of what you see on the scales, and knowing the active ingredient rather than the brand is what lets you carry that understanding between countries. What it does not do is decide your prescription. Kidney function, heart health, hypoglycaemia risk, cost and supply all belong in that decision too, which is why the useful move is to take this to your doctor rather than act on it alone.